Common Stock
- Symbol
- TWST
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
TWSTNASDAQEQUITYCurrent
Item 2.02 Results of Operations and Financial Condition. On November 12, 2026, Twist Bioscience Corporation (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Press release in this filing
Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2026 Financial Results →At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal - more experiments, more iterations, more chances for remarkable discoveries.
Twist Bioscience Corporation · 8-K · Filed 2026-11-12
Exhibit 99.1 Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2026 Financial Results - Record revenue of $459.4 million in Fiscal 2026; Increase of 22% over $376.6 million in Fiscal 2025 - - Record revenue of $126.6 million in 4QFY26; Increase of approximately 28% over $99.0 million in 4QFY25; 15th consecutive quarter of sequential growth - - Gross margin of 52.4% in fiscal 2026, Improvement of 1.7 margin points versus 50.7% in fiscal 2025 - - Fiscal 2027 revenue guidance of $550M-$560M, growth of 21% year over year at the midpoint - - First quarter fiscal 2027 revenue guidance of $130M to $132M, growth of 26% year over year at the midpoint - SOUTH SAN FRANCISCO, Calif. -- (November 12, 2026) - Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today reported financial results and business highlights for the fourth quarter and full year fiscal 2026 ended September 30, 2026. “Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue growth, expanded gross margin and positive adjusted EBITDA in the fourth quarter, all while continuing to broaden our capabilities and strengthen our balance sheet," said …
Open exhibit ↗